243 related articles for article (PubMed ID: 21602310)
21. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
[TBL] [Abstract][Full Text] [Related]
22. Adding HPV16 testing to abnormal cervical smear detection is useful for predicting CIN3: a prospective study.
Tanaka H; Sato H; Sato N; Takahashi O; Ota H; Hirano H; Tanaka T
Acta Obstet Gynecol Scand; 2004 May; 83(5):497-500. PubMed ID: 15059166
[TBL] [Abstract][Full Text] [Related]
23. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.
Castle PE; Lorincz AT; Scott DR; Sherman ME; Glass AG; Rush BB; Wacholder S; Burk RD; Manos MM; Schussler JE; Macomber P; Schiffman M
J Clin Microbiol; 2003 Sep; 41(9):4022-30. PubMed ID: 12958220
[TBL] [Abstract][Full Text] [Related]
24. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
25. Lower cost strategies for triage of human papillomavirus DNA-positive women.
Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
[TBL] [Abstract][Full Text] [Related]
26. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
27. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
[TBL] [Abstract][Full Text] [Related]
28. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
29. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
30. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
[TBL] [Abstract][Full Text] [Related]
32. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
33. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
34. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
[TBL] [Abstract][Full Text] [Related]
35. [High-risk HPV genotyping PCR testing as a means of cervical cancer and precancerous lesions early screening].
Ma L; Cong X; Bian M; Shi M; Wang X; Liu J; Liu H
Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):246-52. PubMed ID: 26080934
[TBL] [Abstract][Full Text] [Related]
36. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
[TBL] [Abstract][Full Text] [Related]
37. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort.
Peto J; Gilham C; Deacon J; Taylor C; Evans C; Binns W; Haywood M; Elanko N; Coleman D; Yule R; Desai M
Br J Cancer; 2004 Aug; 91(5):942-53. PubMed ID: 15292939
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
39. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
40. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
